Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692642 | 0.99 | NOD1 (0.46) | NOD1GLP1RFAAHEPHX2TLR2 | |
| SCHEMBL22692615 | 0.88 | NMT2 (0.47) | NOD1GLP1RFAAHEPHX2TLR2 | |
| SCHEMBL19700526 | 0.87 | MMP3 (0.38) | NOD1 | |
| SCHEMBL19062765 | 0.84 | NMT1 (0.49) | NOD1GLP1RTLR2 | |
| SCHEMBL20053467 | 0.83 | NMT2 (0.41) | NOD1GLP1RTLR2 | |
| SCHEMBL22692638 | 0.83 | NMT2 (0.50) | NOD1GLP1REPHX2TLR2 | |
| SCHEMBL21154993 | 0.83 | NMT2 (0.50) | NOD1GLP1REPHX2TLR2 | |
| SCHEMBL19156036 | 0.82 | NMT2 (0.52) | NOD1GLP1REPHX2TLR2CASP2 | |
| SCHEMBL22227375 | 0.82 | NMT2 (0.52) | NOD1GLP1REPHX2TLR2CASP2 | |
| SCHEMBL21251694 | 0.82 | TLR2 (0.50) | NOD1GLP1RFAAHEPHX2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20210024923-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024923-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | NOD1 1089/4885GLP1R 2760/4885FAAH 4138/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | NOD1 1089/4885GLP1R 2760/4885FAAH 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.